Drugs / RAL
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01837277 Background | Dec 2017 → Jul 2021 | immunodeficiency disease | Fundação Bahiana de Infectologia | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAL | “RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID” NCT01837277 ↗ |